Pathology system used in prostate cancer granted patents
The U.S. Patent and Trademark Office issued patent numbers to cover Aureon Laboratories, Inc.?s systems and methods for evaluating the occurrence of any medical condition in a patient where clinical, imaging, and molecular data are combined and appraised.
The U.S. Patent and Trademark Office issued patent numbers to cover Aureon Laboratories, Inc.’s systems and methods for evaluating the occurrence of any medical condition in a patient where clinical, imaging, and molecular data are combined and appraised.
This approach, known as “systems pathology,” combines several enhanced technologies, including image analysis and biomarker evaluation, with clinical data and advanced mathematics to produce a predictive score indicating the likelihood of disease progression.
The initial application of the systems pathology platform is Prostate Px+, a laboratory developed test that provides a personalized prediction of prostate cancer progression at the time of diagnosis. Eighty-five percent of patients diagnosed with the disease are initially considered low or intermediate risk. Prostate Px+ helps identify patients within this large group who are actually at high risk for progression, thus allowing for timely insight prior to a treatment decision.
Prostate Px+ also identifies those patients with favorable pathology who may have a more indolent course of disease.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
